These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34989088)

  • 1. Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'.
    Doumas M; Patoulias D; Papadopoulos C
    Eur J Heart Fail; 2022 Feb; 24(2):400-401. PubMed ID: 34989088
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to 'Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in subjects with heart failure?' Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'.
    De Biase N; Del Punta L; Pugliese NR
    Eur J Heart Fail; 2022 Feb; 24(2):401. PubMed ID: 34985799
    [No Abstract]   [Full Text] [Related]  

  • 3. The far-reaching beneficial effects of sodium-glucose co-transporter 2 inhibitors in heart failure.
    Crea F
    Eur Heart J; 2022 Aug; 43(31):2907-2910. PubMed ID: 35963617
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.
    Iacobellis G; Baroni MG
    J Endocrinol Invest; 2022 Mar; 45(3):489-495. PubMed ID: 34643917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
    Berendse J; Newenhouse L
    S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
    [No Abstract]   [Full Text] [Related]  

  • 6. Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?
    Katsiki N; Mikhailidis DP
    J Diabetes Complications; 2019 Nov; 33(11):107408. PubMed ID: 31522962
    [No Abstract]   [Full Text] [Related]  

  • 7. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
    Berezin AE; Berezin AA
    Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
    Bauersachs J; Soltani S
    Eur Heart J; 2023 Oct; 44(37):3697-3699. PubMed ID: 37611060
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter 2 inhibitors in heart failure.
    Rosano GMC; Vitale C; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Crea F
    Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.
    Khan MS; Fonarow GC; Greene SJ
    Eur J Heart Fail; 2021 Jun; 23(6):1023-1025. PubMed ID: 33779013
    [No Abstract]   [Full Text] [Related]  

  • 14. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
    Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
    Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Petrie MC; Lee MMY; Docherty KF
    Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
    Díaz-Rodríguez E; Agra RM; Fernández ÁL; Adrio B; García-Caballero T; González-Juanatey JR; Eiras S
    Cardiovasc Res; 2018 Feb; 114(2):336-346. PubMed ID: 29016744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved.
    Afsar B; Afsar RE
    Clin Nutr; 2023 Dec; 42(12):2338-2352. PubMed ID: 37862820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity.
    Yaribeygi H; Maleki M; Butler AE; Jamialahmadi T; Sahebkar A
    Eur J Pharm Sci; 2023 Jan; 180():106322. PubMed ID: 36336279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
    Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C
    Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes.
    Burgeiro A; Fuhrmann A; Cherian S; Espinoza D; Jarak I; Carvalho RA; Loureiro M; Patrício M; Antunes M; Carvalho E
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E550-64. PubMed ID: 26814014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.